NeoGenomics, Inc. (NASDAQ: NEO) Stock Competitors & Peer Comparison
See NEO's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for NEO and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NEO | $19.33 | -1.18% | 496.7M | 148.69 | $0.13 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.64% |
| TMO | $675.00 | -0.50% | 249.1B | 29.09 | $23.16 | +0.27% |
| DHR | $224.49 | +0.32% | 157.8B | 28.14 | $7.98 | +0.64% |
| NTRA | $412.56 | +0.92% | 59.1B | -312.55 | -$1.32 | N/A |
| A | $172.79 | -0.03% | 48.8B | 29.74 | $5.81 | +0.59% |
| IQV | $270.37 | -1.69% | 44.4B | 22.24 | $12.13 | N/A |
| WAT | $433.54 | +0.75% | 42.6B | 31.71 | $13.68 | N/A |
| IDXX | $519.26 | +1.14% | 41B | 36.52 | $14.22 | N/A |
| ILMN | $270.00 | -1.42% | 40.9B | 53.68 | $5.03 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
NEO vs DHR-PB Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, NEO's ROE is -0.06%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, NEO is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for NEO.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
NEO vs TMO Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, TMO has a market cap of 249.1B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while TMO trades at $675.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas TMO's P/E ratio is 29.09. In terms of profitability, NEO's ROE is -0.06%, compared to TMO's ROE of +0.13%. Regarding short-term risk, NEO is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for NEO.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
NEO vs DHR Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, DHR has a market cap of 157.8B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while DHR trades at $224.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas DHR's P/E ratio is 28.14. In terms of profitability, NEO's ROE is -0.06%, compared to DHR's ROE of +0.08%. Regarding short-term risk, NEO is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for NEO.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
NEO vs NTRA Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, NTRA has a market cap of 59.1B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while NTRA trades at $412.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas NTRA's P/E ratio is -312.55. In terms of profitability, NEO's ROE is -0.06%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, NEO is more volatile compared to NTRA. This indicates higher risk in terms of short-term price fluctuations for NEO.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
NEO vs A Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, A has a market cap of 48.8B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while A trades at $172.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas A's P/E ratio is 29.74. In terms of profitability, NEO's ROE is -0.06%, compared to A's ROE of +0.20%. Regarding short-term risk, NEO is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for NEO.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
NEO vs IQV Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, IQV has a market cap of 44.4B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while IQV trades at $270.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas IQV's P/E ratio is 22.24. In terms of profitability, NEO's ROE is -0.06%, compared to IQV's ROE of +0.22%. Regarding short-term risk, NEO is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for NEO.Check IQV's competition here
Waters Corporation (NYSE: WAT)
NEO vs WAT Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, WAT has a market cap of 42.6B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while WAT trades at $433.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas WAT's P/E ratio is 31.71. In terms of profitability, NEO's ROE is -0.06%, compared to WAT's ROE of +0.02%. Regarding short-term risk, NEO is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for NEO.Check WAT's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
NEO vs IDXX Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, IDXX has a market cap of 41B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while IDXX trades at $519.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas IDXX's P/E ratio is 36.52. In terms of profitability, NEO's ROE is -0.06%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, NEO is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for NEO.Check IDXX's competition here
Illumina, Inc. (NASDAQ: ILMN)
NEO vs ILMN Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, ILMN has a market cap of 40.9B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while ILMN trades at $270.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas ILMN's P/E ratio is 53.68. In terms of profitability, NEO's ROE is -0.06%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, NEO is more volatile compared to ILMN. This indicates higher risk in terms of short-term price fluctuations for NEO.Check ILMN's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
NEO vs MTD Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, MTD has a market cap of 30.5B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while MTD trades at $1,511.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas MTD's P/E ratio is 34.73. In terms of profitability, NEO's ROE is -0.06%, compared to MTD's ROE of -12.00%. Regarding short-term risk, NEO is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for NEO.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
NEO vs DGX Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, DGX has a market cap of 26.1B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while DGX trades at $236.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas DGX's P/E ratio is 23.30. In terms of profitability, NEO's ROE is -0.06%, compared to DGX's ROE of +0.14%. Regarding short-term risk, NEO is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for NEO.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
NEO vs LH Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, LH has a market cap of 25.4B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while LH trades at $309.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas LH's P/E ratio is 18.37. In terms of profitability, NEO's ROE is -0.06%, compared to LH's ROE of +0.12%. Regarding short-term risk, NEO is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for NEO.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
NEO vs GH Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, GH has a market cap of 23.7B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while GH trades at $177.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas GH's P/E ratio is -50.56. In terms of profitability, NEO's ROE is -0.06%, compared to GH's ROE of +2.11%. Regarding short-term risk, NEO is more volatile compared to GH. This indicates higher risk in terms of short-term price fluctuations for NEO.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
NEO vs EXAS Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas EXAS's P/E ratio is -95.37. In terms of profitability, NEO's ROE is -0.06%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, NEO is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for NEO.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
NEO vs MEDP Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, MEDP has a market cap of 17.3B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while MEDP trades at $618.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas MEDP's P/E ratio is 36.28. In terms of profitability, NEO's ROE is -0.06%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, NEO is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for NEO.Check MEDP's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
NEO vs ILMNV Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas ILMNV's P/E ratio is N/A. In terms of profitability, NEO's ROE is -0.06%, compared to ILMNV's ROE of N/A. Regarding short-term risk, NEO is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for NEO.Check ILMNV's competition here
Revvity, Inc. (NYSE: RVTY)
NEO vs RVTY Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, RVTY has a market cap of 16.9B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while RVTY trades at $151.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas RVTY's P/E ratio is 28.24. In terms of profitability, NEO's ROE is -0.06%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, NEO is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for NEO.Check RVTY's competition here
PerkinElmer, Inc. (NYSE: PKI)
NEO vs PKI Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas PKI's P/E ratio is 41.45. In terms of profitability, NEO's ROE is -0.06%, compared to PKI's ROE of +0.03%. Regarding short-term risk, NEO is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for NEO.Check PKI's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
NEO vs CRL Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, CRL has a market cap of 14.1B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while CRL trades at $292.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas CRL's P/E ratio is 29.61. In terms of profitability, NEO's ROE is -0.06%, compared to CRL's ROE of -0.08%. Regarding short-term risk, NEO is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for NEO.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
NEO vs ICLR Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, ICLR has a market cap of 13.2B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while ICLR trades at $172.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas ICLR's P/E ratio is 14.06. In terms of profitability, NEO's ROE is -0.06%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, NEO is more volatile compared to ICLR. This indicates higher risk in terms of short-term price fluctuations for NEO.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
NEO vs QGEN Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, QGEN has a market cap of 9.1B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while QGEN trades at $44.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas QGEN's P/E ratio is 18.25. In terms of profitability, NEO's ROE is -0.06%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, NEO is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for NEO.Check QGEN's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
NEO vs BLLN Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, BLLN has a market cap of 5.7B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while BLLN trades at $123.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas BLLN's P/E ratio is 175.83. In terms of profitability, NEO's ROE is -0.06%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, NEO is more volatile compared to BLLN. This indicates higher risk in terms of short-term price fluctuations for NEO.Check BLLN's competition here
RadNet, Inc. (NASDAQ: RDNT)
NEO vs RDNT Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, RDNT has a market cap of 5.6B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while RDNT trades at $70.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas RDNT's P/E ratio is 153.89. In terms of profitability, NEO's ROE is -0.06%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, NEO is more volatile compared to RDNT. This indicates higher risk in terms of short-term price fluctuations for NEO.Check RDNT's competition here
GRAIL Inc. (NASDAQ: GRAL)
NEO vs GRAL Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, GRAL has a market cap of 5.4B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while GRAL trades at $126.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas GRAL's P/E ratio is -12.83. In terms of profitability, NEO's ROE is -0.06%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, NEO is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for NEO.Check GRAL's competition here
Sotera Health Company (NASDAQ: SHC)
NEO vs SHC Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, SHC has a market cap of 5.2B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while SHC trades at $18.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas SHC's P/E ratio is 19.10. In terms of profitability, NEO's ROE is -0.06%, compared to SHC's ROE of +0.27%. Regarding short-term risk, NEO is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for NEO.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
NEO vs SYNH Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas SYNH's P/E ratio is 61.40. In terms of profitability, NEO's ROE is -0.06%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, NEO is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for NEO.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
NEO vs VCYT Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, VCYT has a market cap of 3.6B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while VCYT trades at $45.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas VCYT's P/E ratio is 22.72. In terms of profitability, NEO's ROE is -0.06%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, NEO is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for NEO.Check VCYT's competition here
CareDx, Inc (NASDAQ: CDNA)
NEO vs CDNA Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, CDNA has a market cap of 3.3B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while CDNA trades at $63.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas CDNA's P/E ratio is 75.81. In terms of profitability, NEO's ROE is -0.06%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, NEO is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for NEO.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
NEO vs OLK Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas OLK's P/E ratio is -96.59. In terms of profitability, NEO's ROE is -0.06%, compared to OLK's ROE of -0.07%. Regarding short-term risk, NEO is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for NEO.Check OLK's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
NEO vs WGS Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, WGS has a market cap of 2.6B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while WGS trades at $88.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas WGS's P/E ratio is 245.56. In terms of profitability, NEO's ROE is -0.06%, compared to WGS's ROE of -0.39%. Regarding short-term risk, NEO is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for NEO.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
NEO vs PSNL Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, PSNL has a market cap of 1.8B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while PSNL trades at $16.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas PSNL's P/E ratio is -15.10. In terms of profitability, NEO's ROE is -0.06%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, NEO is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for NEO.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
NEO vs OPK Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while OPK trades at $1.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas OPK's P/E ratio is -6.07. In terms of profitability, NEO's ROE is -0.06%, compared to OPK's ROE of -0.06%. Regarding short-term risk, NEO is more volatile compared to OPK. This indicates higher risk in terms of short-term price fluctuations for NEO.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
NEO vs CSTL Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, CSTL has a market cap of 1.1B. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while CSTL trades at $35.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas CSTL's P/E ratio is -54.26. In terms of profitability, NEO's ROE is -0.06%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, NEO is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for NEO.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
NEO vs FLGT Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, FLGT has a market cap of 630.5M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while FLGT trades at $22.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas FLGT's P/E ratio is 2220.00. In terms of profitability, NEO's ROE is -0.06%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, NEO is more volatile compared to FLGT. This indicates higher risk in terms of short-term price fluctuations for NEO.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
NEO vs GRALV Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas GRALV's P/E ratio is N/A. In terms of profitability, NEO's ROE is -0.06%, compared to GRALV's ROE of N/A. Regarding short-term risk, NEO is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for NEO.Check GRALV's competition here
Global Cord Blood Corporation (NYSE: CO)
NEO vs CO Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas CO's P/E ratio is 5.06. In terms of profitability, NEO's ROE is -0.06%, compared to CO's ROE of +0.11%. Regarding short-term risk, NEO is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for NEO.Check CO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
NEO vs MYGN Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, MYGN has a market cap of 393.8M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while MYGN trades at $4.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas MYGN's P/E ratio is -32.08. In terms of profitability, NEO's ROE is -0.06%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, NEO is more volatile compared to MYGN. This indicates higher risk in terms of short-term price fluctuations for NEO.Check MYGN's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
NEO vs FLDM Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas FLDM's P/E ratio is -4.74. In terms of profitability, NEO's ROE is -0.06%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, NEO is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for NEO.Check FLDM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
NEO vs BDSX Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, BDSX has a market cap of 236.9M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while BDSX trades at $29.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas BDSX's P/E ratio is -9.18. In terms of profitability, NEO's ROE is -0.06%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, NEO is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for NEO.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
NEO vs XGN Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, XGN has a market cap of 210.7M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while XGN trades at $8.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas XGN's P/E ratio is -10.77. In terms of profitability, NEO's ROE is -0.06%, compared to XGN's ROE of -1.22%. Regarding short-term risk, NEO is more volatile compared to XGN. This indicates higher risk in terms of short-term price fluctuations for NEO.Check XGN's competition here
Freenome, Inc. (NASDAQ: FRNM)
NEO vs FRNM Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, FRNM has a market cap of 130.4M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while FRNM trades at $15.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas FRNM's P/E ratio is N/A. In terms of profitability, NEO's ROE is -0.06%, compared to FRNM's ROE of N/A. Regarding short-term risk, NEO is less volatile compared to FRNM. This indicates lower risk in terms of short-term price fluctuations for NEO.Check FRNM's competition here
Genetron Holdings Limited (NASDAQ: GTH)
NEO vs GTH Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas GTH's P/E ratio is -1.11. In terms of profitability, NEO's ROE is -0.06%, compared to GTH's ROE of -1.01%. Regarding short-term risk, NEO is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for NEO.Check GTH's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
NEO vs IMDX Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, IMDX has a market cap of 126.6M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while IMDX trades at $3.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas IMDX's P/E ratio is -2.63. In terms of profitability, NEO's ROE is -0.06%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, NEO is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for NEO.Check IMDX's competition here
Genetic Technologies Limited (NASDAQ: GENE)
NEO vs GENE Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas GENE's P/E ratio is -38.25. In terms of profitability, NEO's ROE is -0.06%, compared to GENE's ROE of -1.85%. Regarding short-term risk, NEO is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for NEO.Check GENE's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
NEO vs SERA Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, SERA has a market cap of 77.9M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while SERA trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas SERA's P/E ratio is -3.14. In terms of profitability, NEO's ROE is -0.06%, compared to SERA's ROE of -0.47%. Regarding short-term risk, NEO is more volatile compared to SERA. This indicates higher risk in terms of short-term price fluctuations for NEO.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
NEO vs PRPO Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, PRPO has a market cap of 42.2M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while PRPO trades at $23.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas PRPO's P/E ratio is -36.38. In terms of profitability, NEO's ROE is -0.06%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, NEO is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for NEO.Check PRPO's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
NEO vs QUCY Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, QUCY has a market cap of 31.4M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while QUCY trades at $1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas QUCY's P/E ratio is -0.06. In terms of profitability, NEO's ROE is -0.06%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, NEO is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for NEO.Check QUCY's competition here
MDxHealth S.A. (NASDAQ: MDXH)
NEO vs MDXH Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, MDXH has a market cap of 29M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while MDXH trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas MDXH's P/E ratio is -0.77. In terms of profitability, NEO's ROE is -0.06%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, NEO is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for NEO.Check MDXH's competition here
Akumin Inc. (NASDAQ: AKU)
NEO vs AKU Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas AKU's P/E ratio is -0.13. In terms of profitability, NEO's ROE is -0.06%, compared to AKU's ROE of -5.32%. Regarding short-term risk, NEO is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for NEO.Check AKU's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
NEO vs BNR Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, BNR has a market cap of 19.7M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while BNR trades at $18.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas BNR's P/E ratio is -21.38. In terms of profitability, NEO's ROE is -0.06%, compared to BNR's ROE of -0.13%. Regarding short-term risk, NEO is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for NEO.Check BNR's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
NEO vs CEMI Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas CEMI's P/E ratio is -0.63. In terms of profitability, NEO's ROE is -0.06%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, NEO is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for NEO.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
NEO vs ENZ Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas ENZ's P/E ratio is -2.24. In terms of profitability, NEO's ROE is -0.06%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, NEO is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for NEO.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
NEO vs PMD Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas PMD's P/E ratio is -5.24. In terms of profitability, NEO's ROE is -0.06%, compared to PMD's ROE of -0.32%. Regarding short-term risk, NEO is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for NEO.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
NEO vs ME Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas ME's P/E ratio is -0.03. In terms of profitability, NEO's ROE is -0.06%, compared to ME's ROE of -42.03%. Regarding short-term risk, NEO is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for NEO.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
NEO vs MYNZ Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, NEO's ROE is -0.06%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, NEO is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for NEO.Check MYNZ's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
NEO vs CHEK Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas CHEK's P/E ratio is -0.43. In terms of profitability, NEO's ROE is -0.06%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, NEO is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for NEO.Check CHEK's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
NEO vs BIAFW Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, BIAFW has a market cap of 9.6M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while BIAFW trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas BIAFW's P/E ratio is 1.02. In terms of profitability, NEO's ROE is -0.06%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, NEO is more volatile compared to BIAFW. This indicates higher risk in terms of short-term price fluctuations for NEO.Check BIAFW's competition here
Centogene N.V. (NASDAQ: CNTG)
NEO vs CNTG Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas CNTG's P/E ratio is -0.23. In terms of profitability, NEO's ROE is -0.06%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, NEO is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for NEO.Check CNTG's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
NEO vs ADVB Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, ADVB has a market cap of 8.8M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while ADVB trades at $6.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas ADVB's P/E ratio is -58.00. In terms of profitability, NEO's ROE is -0.06%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, NEO is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for NEO.Check ADVB's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
NEO vs NDRA Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, NDRA has a market cap of 7.7M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while NDRA trades at $6.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas NDRA's P/E ratio is -0.90. In terms of profitability, NEO's ROE is -0.06%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, NEO is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for NEO.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
NEO vs APDN Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas APDN's P/E ratio is -0.10. In terms of profitability, NEO's ROE is -0.06%, compared to APDN's ROE of -7.23%. Regarding short-term risk, NEO is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for NEO.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
NEO vs NVTA Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas NVTA's P/E ratio is -0.00. In terms of profitability, NEO's ROE is -0.06%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, NEO is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for NEO.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDX)
NEO vs LMDX Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas LMDX's P/E ratio is -0.01. In terms of profitability, NEO's ROE is -0.06%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, NEO is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for NEO.Check LMDX's competition here
LumiraDx Limited (NASDAQ: LMDXW)
NEO vs LMDXW Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, NEO's ROE is -0.06%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, NEO is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for NEO.Check LMDXW's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
NEO vs BIAF Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, BIAF has a market cap of 3.3M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while BIAF trades at $7.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas BIAF's P/E ratio is -0.93. In terms of profitability, NEO's ROE is -0.06%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, NEO is more volatile compared to BIAF. This indicates higher risk in terms of short-term price fluctuations for NEO.Check BIAF's competition here
DermTech, Inc. (NASDAQ: DMTK)
NEO vs DMTK Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas DMTK's P/E ratio is -0.04. In terms of profitability, NEO's ROE is -0.06%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, NEO is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for NEO.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
NEO vs NOTV Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas NOTV's P/E ratio is -0.03. In terms of profitability, NEO's ROE is -0.06%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, NEO is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for NEO.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
NEO vs SQL Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas SQL's P/E ratio is -0.40. In terms of profitability, NEO's ROE is -0.06%, compared to SQL's ROE of -30.46%. Regarding short-term risk, NEO is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for NEO.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
NEO vs AWH Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas AWH's P/E ratio is -0.09. In terms of profitability, NEO's ROE is -0.06%, compared to AWH's ROE of +1.62%. Regarding short-term risk, NEO is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for NEO.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
NEO vs HTGM Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas HTGM's P/E ratio is -0.03. In terms of profitability, NEO's ROE is -0.06%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, NEO is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for NEO.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
NEO vs BIOC Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas BIOC's P/E ratio is -0.01. In terms of profitability, NEO's ROE is -0.06%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, NEO is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for NEO.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
NEO vs SQLLW Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, NEO's ROE is -0.06%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, NEO is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for NEO.Check SQLLW's competition here
iSpecimen Inc. (NASDAQ: ISPC)
NEO vs ISPC Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, ISPC has a market cap of 175K. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while ISPC trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas ISPC's P/E ratio is -0.04. In terms of profitability, NEO's ROE is -0.06%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, NEO is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for NEO.Check ISPC's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
NEO vs WGSWW Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, NEO's ROE is -0.06%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, NEO is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for NEO.Check WGSWW's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
NEO vs NDRAW Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas NDRAW's P/E ratio is N/A. In terms of profitability, NEO's ROE is -0.06%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, NEO is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for NEO.Check NDRAW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
NEO vs PRXL Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas PRXL's P/E ratio is 42.97. In terms of profitability, NEO's ROE is -0.06%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, NEO is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for NEO.Check PRXL's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
NEO vs MEUSW Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas MEUSW's P/E ratio is N/A. In terms of profitability, NEO's ROE is -0.06%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, NEO is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for NEO.Check MEUSW's competition here
Danaher Corporation (NYSE: DHR-PA)
NEO vs DHR-PA Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, NEO's ROE is -0.06%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, NEO is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for NEO.Check DHR-PA's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
NEO vs BNGOW Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas BNGOW's P/E ratio is N/A. In terms of profitability, NEO's ROE is -0.06%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, NEO is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for NEO.Check BNGOW's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
NEO vs OCDX Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas OCDX's P/E ratio is -42.28. In terms of profitability, NEO's ROE is -0.06%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, NEO is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for NEO.Check OCDX's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
NEO vs CHEKZ Comparison September 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 496.7M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, NEO is priced at $19.33 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 148.69, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, NEO's ROE is -0.06%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, NEO is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for NEO.Check CHEKZ's competition here